Shark liver oil supplementation enriches endogenous plasmalogens and reduces markers of dyslipidemia and inflammation

Autor: Adam Alexander T. Smith, Man K.S. Lee, Michelle Cinel, Bronwyn A. Kingwell, Sudip Paul, Paul J. Nestel, Kevin Culham, Natalie A. Mellett, Kaushala S. Jayawardana, Kevin A. Gunawan, Peter J. Meikle, Jacqueline M. Weir, Graeme I. Lancaster, Andrew J. Murphy
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
genetic structures
PE(P)
alkenyl phosphatidylethanolamine
immunometabolism
030204 cardiovascular system & hematology
Biochemistry
LPC(O)
lysoalkylphosphatidylcholine
chemistry.chemical_compound
PC
phosphatidylcholine
0302 clinical medicine
Endocrinology
lipid metabolism
hsCRP
high-sensitivity C-reactive protein
Cross-Over Studies
Middle Aged
metabolic disease
medicine.anatomical_structure
diet and dietary lipids
medicine.symptom
Research Article
Adult
medicine.medical_specialty
Plasmalogen
Plasmalogens
Shark liver oil
Inflammation
QD415-436
03 medical and health sciences
Fish Oils
Double-Blind Method
Internal medicine
White blood cell
Lipidomics
medicine
Animals
Humans
Dyslipidemias
Cholesterol
business.industry
Lipid metabolism
Cell Biology
SLO
shark liver oil
medicine.disease
COH
cholesterol
TG(O)
monoalkyl-diacylglycerol
BH
Benjamini-Hochberg
PC(P)
alkenyl phosphatidylcholine
030104 developmental biology
chemistry
PC(O)
alkyl phosphatidylcholine
Dietary Supplements
Sharks
lipidomics
sense organs
PE(O)
alkyl phosphatidylethanolamine
business
Dyslipidemia
Biomarkers
Zdroj: Journal of Lipid Research
Journal of Lipid Research, Vol 62, Iss, Pp 100092-(2021)
ISSN: 1539-7262
0022-2275
Popis: Plasmalogens are membrane glycerophospholipids with diverse biological functions. Reduced plasmalogen levels have been observed in metabolic diseases; hence, increasing their levels might be beneficial in ameliorating these conditions. Shark liver oil (SLO) is a rich source of alkylglycerols that can be metabolized into plasmalogens. This study was designed to evaluate the impact of SLO supplementation on endogenous plasmalogen levels in individuals with features of metabolic disease. In this randomized, double-blind, placebo-controlled cross-over study, the participants (10 overweight or obese males) received 4-g Alkyrol® (purified SLO) or placebo (methylcellulose) per day for 3 weeks followed by a 3-week washout phase and were then crossed over to 3 weeks of the alternate placebo/Alkyrol® treatment. SLO supplementation led to significant changes in plasma and circulatory white blood cell lipidomes, notably increased levels of plasmalogens and other ether lipids. In addition, SLO supplementation significantly decreased the plasma levels of total free cholesterol, triglycerides, and C-reactive protein. These findings suggest that SLO supplementation can enrich plasma and cellular plasmalogens and this enrichment may provide protection against obesity-related dyslipidemia and inflammation.
Databáze: OpenAIRE
Externí odkaz: